3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
17
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Mantle-Cell
11
Lymphoma
9
Recurrence
5
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Follicular
5
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Lymphatic Diseases
2
Lung Neoplasms
2
Leukemia
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Neoplasms
2
Graft vs Host Disease
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bronchiolitis Obliterans Syndrome
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Metastatic Pancreatic Adenocarcinoma
1
Leukemia, Lymphoid
1
Leukemia, B-Cell
1
Interventions
Temozolomide
14
Radiotherapy
14
Carboplatin
7
Irinotecan
6
Everolimus
5
Filgrastim
4
Carmustine
4
Surgical Procedures, Operative
3
Radiation
3
Paclitaxel
3
Ifosfamide
3
selpercatinib
2
pembrolizumab
2
Trastuzumab
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Methotrexate
2
Imatinib Mesylate
2
IL13-PE38
2
Dasatinib
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
vitespin
1
veliparib
1
vatalanib
1
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
tipifarnib
1
terameprocol
1
temsirolimus
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Central Nervous System Neoplasms
×
ibrutinib
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled